Streetbeat News

Price Targets

FDX

Baird analyst Garrett Holland maintains an Outperform rating on FedEx but lowers the price target from $340 to $320.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 11:07 am

AEIS

Baird analyst Robert Mason has initiated coverage on Advanced Energy Industries (NASDAQ:AEIS) with an Outperform rating and set a price target of $128.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 11:05 am

AHR

JMP Securities analyst Aaron Hecht has maintained a Market Outperform rating on American Healthcares (NYSE:AHR) and raised the price target from $18 to $30.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 11:04 am

DRI

Wedbush analyst Nick Setyan maintains an Outperform rating on Darden Restaurants and raises the price target from $170 to $200.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 10:58 am

CRM

Needham analyst Scott Berg has reiterated a Buy rating on Salesforce (NYSE:CRM) and maintained a price target of $345.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 10:55 am

ALGS

HC Wainwright & Co. has reiterated its Buy rating on Aligos Therapeutics, maintaining a $75 price target. Analyst Ed Arce continues to support the stock, indicating confidence in its potential.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 10:44 am

GMAB

HC Wainwright & Co. has reiterated its Buy rating on Genmab (NASDAQ:GMAB) and maintained a price target of $50, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 10:42 am

CYTK

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for Cytokinetics (NASDAQ:CYTK) and maintained a price target of $90.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 10:37 am

EVAX

HC Wainwright & Co. has reiterated its Buy rating for Evaxion Biotech (NASDAQ:EVAX) and maintained a price target of $14, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 10:35 am

ANGO

HC Wainwright & Co. has reiterated its Buy rating for AngioDynamics (NASDAQ:ANGO) and maintained a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 10:29 am